DL-α-Difluoromethylornithine hydrochloride - Names and Identifiers
Name | Eflornithine
|
Synonyms | Dfmo DFMO Ccris 3295 Brn 2250529 Eflornithine Eflornithine base DIFLUOROMETHYLORNITHINE 2-(difluoromethyl)ornithine 2-(difluoromethyl)-ornithin DIFLUOROMETHYLORNITHINE(RG) alpha-difluromethylornithine H-DL-(A-DIFLUOROMETHYL)ORN-OH α-Difluoromethyl-DL-ornithine D,L-2-DIFLUOROMETHYLORNITHINE alpha-difluoromethylornithine H-.alpha.-Difluoro-Me-DL-Orn-OH DL-α-Difluoromethylornithine hydrochloride 96020-91-6 (Mono-hydrochloride, monohydrate) DL-2-(Difluoromethyl)-ornithinehydrochloride alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid DL-α-Difluoromethylornithine hydrochloride hydrate,2-(Difluoromethyl)ornithine hydrochloride hydrate, DFMO hydrochloride hydrate, Eflornithine hydrochloride hydrate
|
CAS | 67037-37-0 70052-12-9
|
InChI | InChI=1/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12) |
DL-α-Difluoromethylornithine hydrochloride - Physico-chemical Properties
Molecular Formula | C6H12F2N2O2
|
Molar Mass | 182.17 |
Density | 1.1800 (estimate) |
Melting Point | 138 °C |
Boling Point | 347.0±42.0 °C(Predicted) |
Flash Point | 163.7°C |
Solubility | H2O: >10mg/mL, soluble |
Vapor Presure | 9.72E-06mmHg at 25°C |
Appearance | solid |
Color | white |
pKa | 1.22±0.44(Predicted) |
Storage Condition | Store at 0°C |
Refractive Index | 1.462 |
In vivo study | Eflornithine is the only new molecule registered for the treatment of human African trypanosomiasis over the last 50 years. It is the drug used mainly as a back-up for melarsoprol refractory Trypanosoma brucei gambiense cases. In subjects with excessive, unwanted facial hair, eflornithine 15% cream is superior to placebo in reducing hair growth. After 24 weeks' treatment, 58% of eflornithine and 34% of placebo subjects have at least some improvement in facial hirsutism. The hair growth inhibitory activity of eflornithine is significantly enhanced when the eflornithine cream is applied onto a mouse skin area pretreated with microneedles. Treatment of coarctation hypertensive rats with eflornithine results in a normalization of the contractile intensity to KCI and norepinephrine and relaxations to acetylcholine by 14 days of hypertension. |
DL-α-Difluoromethylornithine hydrochloride - Risk and Safety
DL-α-Difluoromethylornithine hydrochloride - Introduction
Eflornithine, also known as Vibrio toxin A(CFA), is A toxin produced by bacteria of the genus Vibrio. The following is a description of the nature, use, formulation and safety information of Eflornithine:
Nature:
- Eflornithine is a white crystalline powder.
-It has a high solubility in water, but its solubility decreases with the increase of temperature.
-This amino acid is acidic in water.
-Its melting point is about 300°C.
Use:
- Eflornithine is an important microbial toxin with powerful immunostimulatory effects.
-It is widely used in the field of Immunology and Immune vaccine research.
- Eflornithine was used to simulate infection and immune responses in animal models.
Preparation Method:
- Eflornithine can be isolated and extracted by Vibrio bacteria culture.
-First, the Vibrio is cultured on an appropriate medium, and then the thallus is separated from the medium by centrifugation and other methods.
-The thallus is broken, and then Eflornithine is extracted using a solvent.
-Finally Eflornithine was purified by filtration, concentration and crystallization.
Safety Information:
- Eflornithine is a strong toxin and should strictly follow safe operating procedures.
-Wear personal protective equipment such as protective gloves, safety glasses and lab coats when handling and handling Eflornithine.
-Avoid direct contact with skin and inhalation of dust.
- Eflornithine should be stored in a dry, cool and well-ventilated place, away from fire and oxidizing agents.
-When disposing of waste, follow relevant environmental regulations and disposal guidelines.
Please note that Eflornithine is a professional compound and needs to follow the corresponding operating procedures and safety measures when used. If necessary, please consult relevant professionals or conduct further research.
Last Update:2024-04-09 21:01:54